Navigation Links
New treatment combination safe for pancreatic cancer patients
Date:6/2/2008

CHICAGO, June 2 Treating pancreatic cancer with a combination of chemotherapy, biotherapy and radiotherapy prior to surgery is safe and may be beneficial for patients, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

In a preliminary study, physicians from the Pancreatic Cancer Center of the University of Pittsburgh Medical Center (UPMC) Cancer Centers examined the safety of combining gemcitabine with bevacizumab and radiotherapy in patients with operable pancreatic cancer. In the study, 14 patients with potentially operable tumors completed the treatment regimen. Following treatment, 10 of the patients were considered eligible for surgery. The incidence of serious adverse events following surgery was not increased in these patients, and several demonstrated significant shrinkage of their tumors before surgery.

The results from the first phase of this two-phase trial are encouraging, said A. James Moser, M.D., lead author of the study, co-director of the Pancreatic Cancer Center and assistant professor of surgery at the University of Pittsburgh School of Medicine. Patients who receive surgery for pancreatic cancer tend to have better outcomes than those who dont, and this treatment allows us to reduce the tumor size prior to surgery.

Given the evidence of tumor-shrinkage from the initial treatment, Dr. Moser and his colleagues are enrolling patients for the second stage of the study to further evaluate the effectiveness of the treatment.

Each year, about 33,000 individuals in the U.S. are diagnosed with pancreatic cancer. It is difficult to diagnose early because symptoms are both rare and varied, and often dont occur until the disease has progressed. Because of this, patients diagnosed with pancreatic cancer typically have a poor prognosis, underscoring the importance of new treatment options.


'/>"/>

Contact: Courtney McCrimmon
McCrimmonCP@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
Source:Eurekalert

Related medicine news :

1. Potential treatments from cryptic genes
2. Acupuncture Eases Side Effects of Head, Neck Cancer Treatments
3. Fertility Specialists Decry Mens Reluctance to Seek Infertility Treatment
4. Treatment guidelines lead to four-fold increase in survival rate for cardiac arrest
5. Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
6. Why some treatments rescue aging skin
7. Study: Child maltreatment victims lose 2 years of quality of life
8. Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Survey Reveals
9. New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference
10. New Veterans Drug Court Focuses on Rehabilitating Our Soldiers Through Mental Health Treatment
11. Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology: